​Why 3 Biotech Stocks Earn Top Tier for Growth Picks

MoneyShow | |

Here's why these biotechs are showing they have franchises that look intact and are growing.

​Ionis: Success in Antisense Technology

MoneyShow | |

IONS continues to execute at a high level.

Inovio Pharmaceuticals (INO): Moving to Phase 3 with First Potential Treatment for HPV Infection of the Cervix

Spotlight Companies | |

Inovio Pharmaceuticals is developing the first potential treatment for HPV infection of the cervix and the first non-surgical treatment for pre-cancerous cervical lesions.

IPO Report: Dermira (DERM)

Francis Gaskins | |

Dermira ($DERM) is a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients. It is based in Redwood

Will New Eylea Application take Regeneron Pharmaceuticals Even Higher?

Michael Teague | |

Late-stage clinical trial data indicating that Regeneron Pharmaceuticals (REGN) and Bayer’s (BAYR) drug Eylea was an effective treatment for the retinal disease known as myopic choroidal

Caterpillar Bumps Up as Share Buyback Plan Offsets weak Earnings Report

Michael Teague | |

Shares for machinery manufacturer Caterpillar (CAT) have risen to as much as $83 on Monday before pulling back slightly to a gain of 2.25 percent, or $82.23 per share, after the company announced

Equities Sector Coverage: Stocks Edged Higher on Election Day

Sector Recap | |

The Dow Jones Industrial Average traded up 13,290.75 still between its 200-day simple moving average at 12,994.20 and its 50-day SMA at 13,341.07. A weekly close above the five-week modified

The 5 Best ETFs for Investors So Far in 2012

Minyanville | |

It’s been a good year thus far for equities. In spite of international and domestic macroeconomic uncertainties, stocks have continued moving in a positive direction since the market bottomed in

Can Biotech's Hottest Names Keep Going?

Equities Editors Desk | |

While the S&P 500 is up about 11.5 percent for the year, navigating through the choppy waters of both U.S. and global economic challenges have not been for investors with weak stomachs. The

Facebook Selling Climax Monday?

George Brooks | |

Investor’s first read - Brooksie’s edge before the openFriday July 27, 2012 9:15 a.m.DJIA: 12,887.93S&P 500: 1360.02Nasdaq Comp.: 2893.25Russell 2000: 777.11TODAY: Facebook (FB) looks like

Sponsored Financial Content

Market Movers